Interview with Enrica Giorgetti, General Director, Farmindustria, Italy
Despite Italy being one of the most important pharmaceutical markets not only in Europe but also in the World, the industry remained quite stable for the last two years and…
Shionogi Europe is a new healthcare company, launched approximately 130 years after the organisation was founded (1878) by Gisaburo Shiono SR. in Doshomachi, Osaka, Japan. The company has grown to become a major research-driven pharmaceutical company dedicated to placing the highest value on patient care.
We are guided by a simple but powerful principle: follow the needs of the patient and the community that surrounds them. This means ensuring that the real-life challenges patients face everyday remain the primary purpose behind R&D, which we believe is a more encouraging way to create clinically-meaningful therapies.
Products and services
We are a research-led organisation, defined by a distinct openness and close partnership approach to creating vaccines and medicines spanning pain, infectious diseases, metabolic disorders, women’s health and oncology.
Our development approach goes hand in hand with the collaborative drug discovery process at the heart of Shionogi. We have an impressive track record of fostering long-term industry partnerships built on trust and a mutual ambition to develop innovative medicines that address unmet medical needs. In 1998 Shionogi licensed one of its new molecules, which later became Crestor (rosuvastatin) to AstraZeneca and still markets this product in Japan today. Other important discoveries include Tivicay and Triumeq, new anti-HIV drugs now marketed by ViiV Healthcare.
Contact
Address: 33 Kingsway, London WC2B 6UF
Tel: +44-203-053-4200
Web: www.shionogi.eu
Despite Italy being one of the most important pharmaceutical markets not only in Europe but also in the World, the industry remained quite stable for the last two years and…
Grunenthal-Formenti relies on Formenti’s 60 years experience in Italy and is the result of the merger of both the German and Italian entities in 96. How would you describe the…
Having led a 26 years long career in Pfizer, you have been involved in a number of different countries including leading markets such as the US and Japan, but also…
You have worked in other countries such as the UK and the US with very large and significant pharmaceutical industries. What would you say is particular about the Italian pharmaceutical…
Since 1982, CNR has been the Italian public body which most contributed to the creation of inventions and innovations. What have been the main strategies behind such a success in…
Over more than 25 years, PAREXEL has expanded its global footprint through a combination of organic growth, alliances, and acquisitions. What was the rationale behind entering Italy in 1995 and…
Roche Italy is one of the companies which went through the most significant re-organization process in the country in the past three years- with important changes in both its marketing…
When you were appointed General Director of the Agenzia Italiana del Farmaco (AIFA) in 2007, the dedicated Investigation Commission highlighted the need for an in-depth reorganization of the Agency in…
“The ball is in the hands of the government,” according to Giorgio Foresti, general manager of Ratiopharm. “Once aware of the opportunities created by generics, politicians will have to make…
The pharmaceutical industry arose from science – and so did Italy’s knowledge based economy. Building on a reputation for innovation carved in the 15th century, when Leonardo Da Vinci, Michelangelo,…
Petrone group was created in 1965, based on your parents’ Carmine and Fernanda’s entrepreneurial spirit. They survived through times of challenges for Italian groups and maintained their independence. In your…
Scharper’s history in the Italian market begins in 1958, but the company as we see it today was really created in the mid nineties, when you founded La Farmochimica Italiana…
See our Cookie Privacy Policy Here
